Generated: April 23, 2017
|Title:||Topical brimonidine tartrate formulations that lack chlorine dioxide|
|Abstract:||Topical solution compositions of brimonidine tartrate are disclosed. The solution compositions lack an oxidative preservative.|
|Inventor(s):||Espino; Ramon L. (Cleburne, TX), Bhagat; Haresh G. (Fort Worth, TX)|
|Assignee:||Alcon, Inc. (Hunenberg, CH)|
|Patent Claims:||1. A topically administrable ophthalmic solution consisting essentially of a) 0.07-0.15% (w/v) brimonidine tartrate; b) 0.001% (w/v) polyquatermium-1; c) 0.3% (w/v) boric acid; d) 0.02% (w/v) sodium borate; e) 1.0-1.5% (w/v) polyvinylpyrrolidone; f) sodium chloride; g) potassium chloride; h) calcium chloride; i) magnesium chloride; j) mannitol; and k) water, wherein the composition has an osmolality of 270-315 mOsm and a pH from 7.0-7.5.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.